Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TmAb-MLINK Duo-MMAE + exatecan
- Development stage
- Preclinical
- Lead developer
- Debiopharm
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**TmAb-MLINK Duo-MMAE + exatecan** is a preclinical, trastuzumab-based dual-payload antibody-drug conjugate developed by Debiopharm using its MLINK Duo linker technology. The HER2-directed trastuzumab antibody delivers monomethyl auristatin E, a microtubule-disrupting payload, and exatecan, a topoisomerase I-inhibitor payload. The MLINK Duo platform is designed to provide high plasma stability and tumor-specific enzymatic release of both payloads; in cell-derived xenograft models, this construct showed antitumor activity and tumor regression in models resistant to corresponding single-payload MMAE or exatecan ADCs. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/86/7_Supplement/1683/781552/Abstract-1683-Enhancing-therapeutic-efficacy-and))
- Other names
- TmAb-MLINK Duo-MMAE/exatecan
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TmAb-MLINK Duo-MMAE + exatecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TmAb-MLINK Duo-MMAE + exatecan.